Clinical trials: OHT - Ocular Hypertension
Glaucoma Open-Angle Primary, Ocular Hypertension
Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
The trial will evaluate the safety and efficacy of 3 dose regimens of H-1337 [0.6% twice daily (b.i.d.), 1.0% b.i.d. and 1.0% once in the morning (q.a.m.), and timolol maleate (0.5%, b.i.d.) in both eyes for 28 days.
- Trial name
- NCT05913232
- Testing
- H-1337 0.6%, H-1337 1.0%, Timolol 0.5%
- Where
- 9 sites in United States
- Volunteers
- 201 people
- Sponsor
- D. Western Therapeutics Institute, Inc.
Glaucoma, Open-Angle, Ocular Hypertension
Study Comparing Quantitative Assessments in Open-angle Glaucoma (OAG) and/or Ocular Hypertension (OHT)
This study will evaluate assessments from the Goniometric Lens compared with those from anterior segment imaging in patients with open-angle glaucoma (OAG) and/or ocular hypertension (OHT).
- Trial name
- NCT01540370
- Testing
- No Treatment
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Allergan
Primary Open Angle Glaucoma
The Effects of Visior on Ocular Hemodynamics
To determine the relationship between the affects of viewing commercially available content through the VISIOR video goggles and ocular blood flow in glaucoma patients and healthy subjects.
- Trial name
- NCT02959593
- Testing
- VISIOR video goggles
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Visior Technologies Ltd.
Open Angle Glaucoma (OAG), Ocular Hypertension (OHT)
iDose TR Administration in an Office-Based Surgery Setting
Clinical in-use observational trial to evaluate the administration of iDose TR (travoprost intracameral implant) in an office-based surgery setting.
- Trial name
- NCT07816692
- Testing
- iDose TR (travoprost intracameral implant) 75 µg
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Glaukos Corporation
Ocular Hypertension, Open Angle Glaucoma
Study of AR-13324 in Patients With Elevated Intraocular Pressure
In this double-masked, vehicle-controlled, dose-response study, subjects will be randomized to receive AR-13324 Ophthalmic Solution 0.01%, 0.02%, and 0.04% or its vehicle (one eye), once daily (QD)in the morning (AM) for 7 days.
- Trial name
- NCT01528787
- Testing
- AR-13324 Ophthalmic Solution 0.01%, AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.04%
- Where
- 11 sites in United States
- Volunteers
- 85 people
- Sponsor
- Aerie Pharmaceuticals
Glaucoma
Perimetric Testing With Virtual Reality
Perimetry is an essential component in the diagnosis and monitoring of glaucoma. Since the advent of Standard Automated Perimetry (SAP), one of the clinical standards has been the Humphrey Field Analyzer (HFA, Carl Zeiss AG…
- Trial name
- NCT06549010
- Testing
- Perimetric test
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Envision Health Technologies, Inc.
Open-angle Glaucoma or Ocular Hypertension
Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension
The purpose of this study is to investigate the safety and efficacy of four concentrations of DE-117 ophthalmic solution.
- Trial name
- NCT01868126
- Testing
- DE-117 ophthalmic solution, latanoprost ophthalmic solution
- Where
- 7 sites in United States
- Volunteers
- 91 people
- Sponsor
- Santen Inc.
Open Angle Glaucoma, Ocular Hypertension
A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma
To demonstrate statistical superiority of the combination of latanoprost and timolol to the individual therapy of latanoprost and timolol based on intraocular pressure measurements at 8 AM, 10 AM, 4 PM at weeks 2, 6 and 12.
- Trial name
- NCT00277498
- Testing
- Xalacom, Xalatan, Timolol
- Where
- 64 sites in United States
- Volunteers
- 528 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Glaucoma, Open-Angle, Glaucoma, Narrow Angle
Study of a Cilioscleral Interposition Device (CID) SV22 in Patients With Primary Open Angle Glaucoma and Narrow Angle Glaucoma
The purpose of this study is to evaluate the safety and effectiveness of implanting a new version of an interposition supraciliary implant (SV22) as a stand-alone therapy for lowering intraocular pressure (IOP) in patients with…
- Trial name
- SAFARI 3 (NCT05236439)
- Testing
- Interposition supraciliary implant
- Where
- Armenia
- Volunteers
- 57 people
- Sponsor
- Ciliatech
Open Angle Glaucoma (OAG)
Safety and Performance Study of the CyPass System Applier Model 241
This is a retrospective chart review of cases in which the CyPass Micro-Stent was implanted using the Model 241 Applier. The objective of this study is to characterize and evaluate the safety of the Model 241 Applier when used…
- Trial name
- RePASS (NCT02228577)
- Where
- Germany
- Volunteers
- 172 people
- Sponsor
- Transcend Medical, Inc.
Primary Open-Angle Glaucoma, Ocular Hypertension
Dose-Ranging Study of the Bimatoprost Ocular Insert
The Bimatoprost Ocular Insert is intended to provide sustained delivery of bimatoprost to the ocular surface to lower the intraocular pressure (IOP) in patients with Open-Angle Glaucoma or Ocular Hypertension.
- Trial name
- NCT02358369
- Testing
- Bimatoprost, Timolol 0.5%
- Where
- 10 sites in United States
- Volunteers
- 156 people
- Sponsor
- ForSight Vision5, Inc.
Glaucoma, Glaucoma, Open-Angle
AqueSys Microfistula Implant in Refractory Glaucoma
To establish the safety and performance of the AqueSys Microfistula Implant in eyes with refractory glaucoma.
- Trial name
- NCT01640756
- Testing
- AqueSys Microfistula Implant
- Where
- 14 sites in United States
- Volunteers
- 60 people
- Sponsor
- AqueSys, Inc.
Glaucoma
Combigan Ophthalmic Solution(Brimonidine 0.2% and Timolol 0.5%)With Latanoprost Compared With Latanoprost Monotherapy
This study is to evaluate the efficacy and safety of Combigan ophthalmic solution in combination with Latanoprost when the therapy is swiched from Latanoprost monotherapy in patient with Glaucoma or ocular hypertension.
- Trial name
- NCT00442312
- Testing
- Combigan Ophthalmic Solutiom
- Where
- Taiwan
- Volunteers
- 43 people
- Sponsor
- Genovate Biotechnology Co., Ltd.,
Open-angle Glaucoma, Ocular Hypertension
A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
The purpose of this study is to assess the comfort of a glaucoma therapy in patients with open-angle glaucoma or ocular hypertension
- Trial name
- NCT00326092
- Testing
- Brinzolamide/Timolol
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- Alcon Research
Open-Angle Glaucoma, Ocular Hypertension
Safety and Intraocular Pressure (IOP)-Lowering Efficacy of AL-39256 in Patients With Open-Angle Glaucoma or Ocular Hypertension
The purpose of this study is to evaluate the safety and intraocular pressure (IOP)-lowering efficacy of AL-39256 in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00761709
- Testing
- AL-39256 Ophthalmic Suspension, 1%, Latanoprost Ophthalmic Solution, 0.005%, Vehicle
- Volunteers
- 104 people
- Sponsor
- Alcon Research
Glaucoma, Open-Angle, Ocular Hypertension
A Study of Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
This is an observational study of Lumigan® 0.01% (bimatoprost) treatment in clinical practice for patients with Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
- Trial name
- NCT01632423
- Testing
- bimatoprost 0.01%
- Where
- Germany
- Volunteers
- 10,337 people
- Sponsor
- Allergan
Glaucoma, Open-Angle
Study of a Novel Interposition Supraciliary Implant in Patients With Open Angle Glaucoma (SAFARI 2)
The purpose of this study is to evaluate the safety and effectiveness of implanting 2 novel interposition supraciliary implant as a stand-alone therapy for lowering intraocular pressure (IOP) in patients with primary open angle…
- Trial name
- SAFARI 2 (NCT04770324)
- Testing
- Interposition supraciliary implant
- Where
- Armenia
- Volunteers
- 22 people
- Sponsor
- Ciliatech
Primary Open-angle Glaucoma, Ocular Hypertension
Safety/Efficacy Study: OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension
This is a study of the safety, tolerability, pharmacokinetics (measurement of drug levels in the blood), and intraocular pressure lowering effects of OPA-6566 ophthalmic solution in subjects with primary open-angle glaucoma or…
- Trial name
- NCT01410188
- Testing
- OPA-6566, Latanoprost
- Where
- 9 sites in United States
- Volunteers
- 160 people
- Sponsor
- Kubota Vision Inc.
Open-angle Glaucoma
Open-angle Glaucoma Subjects on One Ocular Hypotensive Medication Randomized to Treatment With Two Trabecular Micro-bypass Stents or Selective Laser Trabeculoplasty
Evaluation of intraocular pressure (IOP) lowering effect of two iStent stents versus a SLT procedure in subjects with open-angle glaucoma on one ocular hypotensive medication.
- Trial name
- NCT01444105
- Testing
- iStent, SLT
- Where
- Armenia
- Volunteers
- 80 people
- Sponsor
- Glaukos Corporation
Retinal Disease, Glaucoma
Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes
This study is designed to evaluate and compare in-tissue performance of OCT scans on the new Optos P200TE, versus the predicate Optos Spectral OCT/SLO device.
- Trial name
- NCT02921568
- Testing
- P200TE, Spectral OCT/SLO
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Optos, PLC